HPV Induced Cancers is under clinical development by Theravectys and currently in Phase II for Human Papillomavirus (HPV) Associated Cancer. According to GlobalData, Phase II drugs for Human Papillomavirus (HPV) Associated Cancer have a 16% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how HPV Induced Cancers’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
HPV Induced Cancers overview
Vaccine candidate is under development for the treatment of HPV-associated cervical, oropharyngeal cancer, anal cancer and throat cancer. It is composed of lentiviral vectors incorporating several tumor-associated antigens that boost the immune response of the body.
Theravectys overview
Theravectys is a clinical development biotech company that develops new generation therapeutic vaccines and immunotherapies. The company develops viral vectors vaccines to support body and prepare against future infections by pre-exposing immune system to partial, dead, inactivated or milder, and attenuated pathogens. It provides lentiviral vectors and t-cell, which includes CAR-T and gene therapy vaccines for many indications. TheraVectys vaccine for human and veterinary indications in oncology and infectious diseases such as HIV, HBV, Malaria, zika, Rift valley fever virus, melanoma, colon cancer, prostate cancer and various solid cancer. It partners with other biotech companies to develop its lentiviral vector platform. Theravectys is headquartered in Paris, France
For a complete picture of HPV Induced Cancers’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
